Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early versus Late Discontinuation of Maintenance Therapy in Multiple Myeloma.
Nunnelee J, Cottini F, Zhao Q, Faisal MS, Elder P, Rosko A, Bumma N, Khan A, Umyarova E, Devarakonda S, Benson DM, Efebera YA, Sharma N. Nunnelee J, et al. Among authors: elder p. J Clin Med. 2022 Sep 29;11(19):5794. doi: 10.3390/jcm11195794. J Clin Med. 2022. PMID: 36233663 Free PMC article.
Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.
Hamadani M, Blum W, Phillips G, Elder P, Andritsos L, Hofmeister C, O'Donnell L, Klisovic R, Penza S, Garzon R, Krugh D, Lin T, Bechtel T, Benson DM, Byrd JC, Marcucci G, Devine SM. Hamadani M, et al. Among authors: elder p. Biol Blood Marrow Transplant. 2009 Nov;15(11):1422-30. doi: 10.1016/j.bbmt.2009.07.006. Epub 2009 Sep 1. Biol Blood Marrow Transplant. 2009. PMID: 19822302 Free PMC article. Clinical Trial.
Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning.
Hamadani M, Craig M, Phillips GS, Abraham J, Tse W, Cumpston A, Gibson L, Remick SC, Bunner P, Leadmon S, Elder P, Hofmeister C, Penza S, Efebera Y, Andritsos L, Garzon R, Benson DM Jr, Blum W, Devine SM. Hamadani M, et al. Among authors: elder p. Hematol Oncol. 2011 Dec;29(4):202-10. doi: 10.1002/hon.985. Epub 2011 Feb 28. Hematol Oncol. 2011. PMID: 21360728 Free PMC article.
Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.
Dunavin NC, Wei L, Elder P, Phillips GS, Benson DM Jr, Hofmeister CC, Penza S, Greenfield C, Rose KS, Rieser G, Merritt L, Ketcham J, Heerema N, Byrd JC, Devine SM, Efebera YA. Dunavin NC, et al. Among authors: elder p. Leuk Lymphoma. 2013 Aug;54(8):1658-64. doi: 10.3109/10428194.2012.751528. Epub 2012 Dec 31. Leuk Lymphoma. 2013. PMID: 23194056 Free PMC article.
The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma.
Jaglowski SM, Ruppert AS, Hofmeister CC, Elder P, Blum W, Klisovic R, Vasu S, Penza S, Efebera YA, Benson DM Jr, Devine SM, Andritsos LA. Jaglowski SM, et al. Among authors: elder p. Bone Marrow Transplant. 2014 Oct;49(10):1323-9. doi: 10.1038/bmt.2014.155. Epub 2014 Jul 28. Bone Marrow Transplant. 2014. PMID: 25068419 Free PMC article.
221 results